IBM Stock Fell 22% in the Third Quarter. History Says It's Usually Higher a Year Later.

IBM shares fell about 22% in Q3 to roughly $220, including a record 25% one-day drop on July 14 after the company described preliminary Q2 results as disappointing. Software revenue growth slowed from 14% year over year in Q4 2025 to 5% in Q2 2026, and management cut its full-year constant-currency revenue growth forecast to 4%-5% from more than 5%. Historical rebounds after large quarterly declines often coincided with a rising market, but IBM is lagging the S&P 500 and the article says a software-growth rebound is needed to support the stock.

Analysis

IBM: earnings execution matters more than rebound statistics. The historical rebound rate is a weak signal: it is conditional on the market regime, based on a small sample, and does not establish that IBM’s operating trajectory has turned. The first-quarter episode is the more relevant analogue: market strength did not protect the shares when company-specific growth expectations deteriorated.

The key near-term test is whether software growth stabilizes at the October 21 report and management can defend its outlook. A miss would put pressure on both forward estimates and the credibility of the software-led growth case; the lower multiple alone is not a catalyst if consensus earnings estimates have not caught up. Conversely, stabilization could prompt a sharp relief rally after the selloff, so outright shorting into the report has asymmetric squeeze risk.

Over 6–18 months, AI-assisted COBOL modernization cuts both ways. Cheaper migration may accelerate customer moves away from IBM mainframes and weaken the value of legacy expertise; it may also expand modernization work that IBM or other consultants can monetize. The decisive variable is who captures the work and whether modernization revenue offsets any erosion in recurring mainframe-related economics—not the tool announcement itself. Verify software growth by subsegment, mainframe demand, and guidance before treating this as a durable impairment.

Key Decisions for Investors

• Ahead of the October 21 report, prefer a modest relative underweight in IBM versus the S&P 500 over an outright short: this expresses company-specific execution risk while limiting exposure to a broad-market rally. Reassess after results; avoid adding into a pre-report squeeze without confirmation.
• Bearish thesis confirmation: software growth continues to decelerate, management trims or cannot reaffirm its outlook, or forward estimates move lower. In that case, maintain the relative underweight and reassess whether the apparent valuation discount is using stale earnings estimates.
• Falsifier: software growth stabilizes or reaccelerates and guidance is maintained or improved, with evidence that AI modernization demand is being monetized without weakening core mainframe economics. Cover the underweight rather than relying on historical rebound statistics.
• Watch, do not assume: request segment-level evidence on modernization wins, customer migration/retention, and recurring mainframe demand. Without it, the COBOL-tool impact remains a plausible structural risk—not proof that IBM has already lost those revenues.